Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antithrombotic agents]

A Keréveur1, M M Samama

  • 1Service d'Hématologie biologique, Hôtel-Dieu, Paris.

Presse Medicale (Paris, France : 1983)
|December 9, 1995
PubMed
Summary
This summary is machine-generated.

New antithrombotic agents are crucial for preventing and treating thrombosis. Research focuses on novel anticoagulants and antiplatelet drugs, with combination therapies considered for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis.

Hematology (Amsterdam, Netherlands)·2016
Same author

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].

Annales francaises d'anesthesie et de reanimation·2013
Same author

[Hemorrhagic accidents of the new oral anticoagulants and coagulation assays].

Journal des maladies vasculaires·2013
Same author

Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

Thrombosis and haemostasis·2011
Same author

[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

Journal des maladies vasculaires·2011
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Pharmacology and Medicine
  • Cardiovascular Research

Context:

  • Ongoing need for effective antithrombotic therapies.
  • Venous thrombosis management relies on anticoagulants like low molecular weight heparins.
  • Arterial thrombosis involves platelets, with agents like c7E3 and integrelin showing efficacy.

Purpose:

  • To review current developments in antithrombotic agents.
  • To discuss the roles of anticoagulants and antiplatelet agents in thrombosis.
  • To highlight research objectives, including oral antithrombin and anti-platelet-glycoprotein IIb/IIIa agents.

Summary:

  • Development of novel antithrombotic compounds is driven by clinical needs.
  • Anticoagulants (e.g., low molecular weight heparins, hirudin) are key for venous thrombosis.

Related Experiment Videos

  • Antiplatelet agents (e.g., c7E3, integrelin) are effective for arterial thrombosis.
  • Thrombin's role suggests anticoagulants may also prevent arterial clots, alone or combined.
  • Oral antithrombin and anti-platelet-glycoprotein IIb/IIIa agents are major research goals.

    • Impact:

    • Combination therapies may be used for high-risk thrombosis patients.
    • Careful laboratory monitoring is essential due to bleeding risks.
    • Future research aims for ideal antithrombotic agents with improved safety profiles.